In patients in whom clinical variables are worrisome for a greater disease burden than that suggested by our current imaging standards (CT or MRI) (i.e. acute elevation in AFP, portal vein thrombosis, multifocal lesions, tumor size > 4.5 cm) 11C-acetate opens up the possibility of improving our understanding of disease burden. This evidence concerns the gene AFP and neoplasm.